Bio-Path Holdings to Present at the 14th Annual BIO Investor Forum
October 13 2015 - 4:05PM
Business Wire
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (Bio-Path), a
biotechnology company developing a liposomal delivery technology
for nucleic acid cancer drugs, today announced that Peter Nielsen,
President and Chief Executive Officer, will present a company
overview at the 14th Annual BIO Investor Forum Conference in San
Francisco on Tuesday, October 20, 2015 at 3:30 p.m. Pacific Time
(6:30pm Eastern Time).
A live webcast of Mr. Nielsen’s presentation will be available
in the Investor/Media section of Bio-Path’s website:
www.biopathholdings.com.
About Bio-Path Holdings,
Inc.
Bio-Path is a biotechnology company focused on developing
therapeutic products utilizing its proprietary liposomal delivery
technology designed to systemically distribute nucleic acid drugs
throughout the human body with a simple intravenous transfusion.
Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase 2
study for blood cancers and in preclinical studies for triple
negative and inflammatory breast cancers. Bio-Path’s second drug
candidate, also a liposomal antisense drug, is ready for the clinic
where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Forward-Looking
Statements
Any statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties, including Bio-Path’s ability to raise needed
additional capital on a timely basis in order for it to continue
its operations, have success in the clinical development of its
technologies, the timing of enrollment and release of data in such
clinical studies and the accuracy of such data, limited patient
populations of early stage clinical studies and the possibility
that results from later stage clinical trials with much larger
patient populations may not be consistent with earlier stage
clinical trials, and such other risks which are identified in the
Company's most recent Annual Report on Form 10-K and in any
subsequent quarterly reports on Form 10-Q. These documents are
available on request from Bio-Path Holdings or at www.sec.gov.
Bio-Path disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151013006480/en/
InvestorsBio-Path Holdings, Inc.Kara Andress,
832-742-1357Investor RelationsorRx Communications Group, LLCSteve
Silver, 917-322-2569ssilver@rxir.comorMedia6 DegreesTony
Plohoros, 908-591-2839tplohoros@6degreespr.com
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Apr 2023 to Apr 2024